Magnetic resonance spectroscopy in patients with locally confined prostate cancer: Association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score

European Radiology

Volumn 17, Issue 2, 2007, Pages 371-378

  Mueller Lisse, Ullrich G ^b   Swanson, Mark G ^a   Vigneron, Daniel B ^a   Kurhanewicz, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Citrate; Gleason score; Gleason sum; Hormone deprivation therapy; Magnetic resonance; Magnetic resonance spectroscopy; Prostate cancer; Prostate metabolism; Prostate specific antigen (PSA)

Indexed keywords

BICALUTAMIDE; CHOLINE; CITRIC ACID; CREATINE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; ANGIOGENESIS INHIBITORS; ATROPHY; BIOPSY; CHOLINE; CITRIC ACID; CROSS-SECTIONAL STUDIES; GONADOTROPIN-RELEASING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33846404869     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-006-0321-3     Document Type: Article

References (38)

1. Costello LC, Franklin RB (1991) Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991:25-46
2. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P (1995) Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy. Urology 45:459-466
3. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 198:795-805
4. Costello LC, Franklin RB, Narayan P (1999) Citrate in the diagnosis of prostate cancer. Prostate 38:237-245
5. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB (2002) Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 16:451-463
6. Mueller-Lisse UG, Scherr M (2003) 1H-MR-Spektroskopie der Prostata: Ein Überblick. Radiologe 43:481-488
7. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N,Sullivan LD (1996) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155:213-219
8. Costello LC, Franklin RB (1991) Concepts of citrate production and secretion by prostate. 2. Hormonal relationships in normal and neoplastic prostate. Prostate 19:181-205
9. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J (2001) Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 46:49-57
10. Mueller-Lisse UG, Vigneron DB, Hricak H, Swanson MG, Carroll PR, Bessette A, Scheidler J, Srivastava A, Males RG, Cha I, Kurhanewicz J (2001) Localized prostate cancer: Effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: Clinicopathologic case-controlled study. Radiology 221:380-390
11. Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS (1995) Pathology of androgen deprivation therapy in prostate carcinoma: A comparative study of 173 patients. Cancer 75:1634-1641
12. Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, Reuter VE, Begg CB, Fair WR (1997) Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol 79:432-438
13. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Tetu B, et al (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial. Clin Invest Med 16:499-509
14. Solomon MH, McHugh TA, Dorr RP, Lee F, Siders DB (1993) Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 16:532-538
15. Vailancourt L, Ttu B, Fradet Y et al (1996) Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study. Am J Surg Pathol 20:86-93
16. van Poppel H, de Ridder D, Elgamal AA, van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L (1995) Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial: The Belgian Uro-Oncological Study Group. J Urol 154:429-434
17. Wieder JA, Soloway MS (1998) Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 160:299-315
18. Witjes WP, Schulman CC, Debruyne FM (1997) Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma: The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 49:65-69
19. Zelefsky MJ, Harrison A (1997) Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 49(3A Suppl):38-45
20. Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD (2000) Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56:289-294
21. Klotz L, Gleave M, Goldenberg SL (2000) Neoadjuvant hormone therapy: The Canadian trials. Mol Urol 4:233-239
22. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ (2001) Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58:240-245
23. Mueller-Lisse UG, Heuck AF, Schneede P, Muschter R, Scheidler J, Hofstetter AG, Reiser MF (1996) Postoperative MRI in patients undergoing interstitial laser coagulation thermotherapy of benign prostatic hyperplasia. J Comput Assist Tomogr 20:273-278
24. Star LJ, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB (1997) Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 38:311-321
25. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508:333-348
26. Heerschap A, Jager GJ, van, der, Graaf, M, Barentsz JO, Ruijs SH (1997) Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 37:204-213
27. Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, Lutz O (1993) Localized proton MR spectroscopy of citrate in vitro and of the prostate in vivo at 1.5 T. Magn Reson Med 29:38-43
28. Moyher SE, Vigneron DB, Nelson SJ (1995) Surface coil MR imaging of the human brain with an analytic reception profile correction. J Magn Reson Imaging 5:139-144
29. Nelson SJ, Brown TR (1987) A new method for automatic quantification of 1-D spectra with low signal to noise ratio. J Magn Reson 75:229-243
30. Glantz SA (1997) Primer of biostatistics, 4th edn. McGraw-Hill, New York
31. Fair WR, Cookson MS, Stroumbakis N et al (1997) The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49:46-55
32. Lee F, Siders DB, McHugh TA, Solomon MH, Klamerus ML (1997) Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Anticancer Res 17:1507-1510
33. Leibowitz RL, Tucker SJ (2001) Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients. Oncologist 6:177-182
34. Peyromaure M, Delongchamps NB, Debre B, Zerbib M (2005) Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: Long-term experience. Urology 65:724-729
35. Gulley JL, Figg WD, Steinberg SM, Carter J, Hussain MH, Dahut WL (2005) A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173:1567-1571
36. Lichy MP, Pintaske J, Kottke R, Machann J, Anastasiadis A, Roell S, Hennenlotter J, Diergarten T, Schick F, Stenzl A, Claussen CD, Schlemmer HP (2005) 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: A feasibility study. Eur Radiol 15:653-660
37. Rouviere O, Hartman RP, Lyonnet D (2006) Prostate MR imaging at high-field strength: Evolution or revolution? Eur Radiol 16:276-284
38. Wetter A, Hubner F, Lehnert T, Fliessbach K, Vorbuchner M, Roell S, Zangos S, Luboldt W, Vogl TJ (2005) Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: Technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol 15:645-652